1. Medtech Insight
  2. >>Business

Edwards Adds To Wide Range Of Approaches To Mitral Repair

 
• By Reed Miller

Harpoon is a minimally invasive surgery device that complements Edwards pipeline of transcatheter mitral and septal valve repair and replacement technologies, which now includes at least six technologies at various stages of development, and is one of the company's top R&D priorities.

Less-invasive mitral valve and tricuspid valve repair is the next major for valve technology now that transcatheter aortic valve replacement (TAVR) systems, like Edwards' market-leading Sapien line, are rapidly taking market share from surgical valves, and is being pursued both by the major surgical valve companies, Edwards and Medtronic PLC as well as small start-ups like 4C Medical Technologies and MVRx, Inc. But Abbott Laboratories Inc.'s MitraClip is the only FDA-approved transcatheter mitral repair device. (Also see "Starts & Stops: Medtronic's TMVR News Closes Big Month For Trial Announcements" - Medtech Insight, 3 November, 2017.)

"We are aggressively pursuing a whole toolbox of therapies for mitral and tricuspid therapies," Edwards CEO Michael Mussallem said during Edwards' Dec. 8 investors conference. "This is a group of...

More from Deals

More from Business

Edwards Lifesciences Holds 2025 EPS Outlook Despite Tariff Headwind

 
• By Shubham Singh

The brunt of the tariff exposure stems from Singapore and Costa Rica, which together account for an estimated 70% to 80% of the tariff-related cost burden. Less than 10% of the exposure is tied to China.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.